Related Experiment Videos
Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and
Insights
Maternal use of meprobamate or chlordiazepoxide during pregnancy did not increase risks for birth defects or developmental issues in children. This large study found no significant differences in malformations, death rates, or neurodevelopmental outcomes for exposed offspring.
Area of Science:
- Perinatal medicine
- Pharmacology
- Developmental toxicology
Background:
- Maternal use of anxiolytic medications during pregnancy is common.
- Concerns exist regarding potential teratogenic effects of meprobamate and chlordiazepoxide.
- Previous studies on these drug exposures have yielded mixed results.
Purpose of the Study:
- To evaluate the association between prenatal exposure to meprobamate or chlordiazepoxide and adverse offspring outcomes.
- To assess the impact of these medications on malformation rates, mortality, and neurodevelopment.
Main Methods:
- A large-scale follow-up study involving over 50,000 pregnancies.
- Comparison of outcomes in 1,870 children exposed in utero to meprobamate or chlordiazepoxide versus 48,412 unexposed children.
- Assessment of malformations, mortality (stillbirth to age four), and neurodevelopmental scores (at 8 months and 4 years).
Main Results:
- No significant differences in overall malformation rates between exposed and unexposed groups (6.5% in total cohort).
- Similar rates of specific malformations and no increased mortality (4.4% in total cohort) with prenatal exposure.
- No evidence of drug-induced brain damage based on mental, motor, and intelligence quotient scores at specified ages.
Conclusions:
- Prenatal exposure to meprobamate or chlordiazepoxide is not associated with an increased risk of major malformations.
- Antenatal exposure to these medications does not appear to elevate mortality rates or cause detectable neurodevelopmental deficits.
- The findings suggest these anxiolytics may be relatively safe for use during pregnancy regarding major congenital anomalies and developmental outcomes.
Abstract:
In a follow-up study of 50,282 pregnancies (lasting at least five lunar months) and the offspring, malformations identified before the first birthday, or at death before the fourth birthday, were identified in 3248 children (6.5 per cent). A total of 1870 children exposed in utero to meprobamate or chlordiazepoxide were compared with 48,412 children who were not. No significant differences were found either overall or in specific outcomes; rates were also similar when exposures occurred during the first trimester or at other times during pregnancy. Deaths (stillbirth to the fourth birthday) occurred in 2227 children (4.4 per cent), and there was no evidence that antenatal exposure to either drug increased the death rate. Finally, as judged by mental and motor scores at the age of eight months, and intelligence quotient scores at four years, there was no evidence that the drugs cause brain damage.